In April 2020, CoSara, a joint venture with Synbiotics, became the first company headquartered in India to get a license to manufacture coronavirus test kits
In particular, the Indian media have noted the extraordinary efforts of a CoSara team of six women who have increased capacity from roughly 8,000 coronavirus PCR tests per day a year ago to around 40,000 per day now.
Co-Diagnostics Inc (NASDAQ:CODX) has noted that its Indian manufacturing facility, CoSara Diagnostics Pvt Ltd, has garnered media attention for its actions to provide much-needed coronavirus (COVID-19) diagnostics as a wave of infections has led to the world’s worst outbreak since the pandemic began.
An article in the Times of India, as well as other media sources, have discussed the increased capacity that has resulted from CoSara’s efforts to provide test kits and technical support for its government and private lab customers, Co-Diagnostics said.
In particular, the company said the media have noted the extraordinary efforts of a CoSara team of six women who have worked to increase capacity at the manufacturing facility from roughly 8,000 COVID-19 PCR tests per day a year ago to around 40,000 per day now – after being one of the first companies to provide PCR test kits to the state of Gujarat.
Utah-based Co-Diagnostics said CoSara – a joint venture with Synbiotics Ltd – has also been highlighted in several news outlets as one of six companies that India would depend on to win the fight against COVID-19 and has remained steadfast through the pandemic, manufacturing over two million tests.
The company said CoSara’s “dedication to the Indian people” in providing quality, real-time PCR tests has expanded its territory to about 160 current customers, which includes equipment installation in 73 laboratories, over 40 of which did not have access to PCR technology prior to becoming CoSara customers. CoSara’s partners and distributors also assisted in setting up nearly a dozen labs from the ground up.
Last week, Co-Diagnostics shipped an emergency supply of raw test materials to CoSara to help combat the surge of cases, which comes as the company marks the two-year anniversary of the manufacturing facility’s inauguration. In April 2020, the CoSara JV became the first company headquartered in India to get a license to manufacture COVID-19 test kits.
“CoSara forms an integral part of our mission to bring high-quality, affordable molecular diagnostics solutions to the world, especially to the people and countries who need them the most,” said Co-Diagnostics CEO Dwight Egan said in a statement.
“Nowhere is that more applicable than India as this unprecedented surge has seen the need for gold-standard PCR diagnostics reach heights that were unheard of prior to the global pandemic, and at pricing levels that many companies are unable to match. We are pleased to be able to play a role in this crisis through our participation in the joint venture.”
Egan can be seen talking about the escalating coronavirus crisis in India and how it could have ramifications for the world’s handling of the pandemic in an interview with CNBC.